HIGH-GRADE ASTROCYTOMA TREATMENT: EFFICACY OF ZOTIRACICLIB AND TEMOZOLOMIDE COMBINATION THERAPY IN A PHASE I CLINICAL TRIAL

Abstract

High-grade astrocytoma is common and aggressive type of the
brain tumor it causes cancer-related death in most times. The
earliest diagnosis and effective anti-tumor agents can help to
prolong the survival time of the patients. Zotiraciclib a cyclindependent kinase 9 (CDK9) inhibitor is known as potential agent
for treating high-grade astrocytoma. This two-stage phase 1
clinical trial established maximum tolerated dose (MTD) of
Zotiraciclib with the Temozolomide. The study conducted in to
branch dose-dense (Arm1) and metronomic (Arm2). 53 percents
were covered during the study and 10% of initial patients finished
the entire course of treatment. Zotiraciclib and Temozolomide
used in high-grade astrocytoma treatment process represented
synergetic effect. These combined drugs are safe in the treatment
of HGA.